Skip to content

Belite Bio

US · BLTE #1866 by market cap Listed 2022
127.38 -23.64 -15.65%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Recent news

  • Rating change
    Cantor Fitzgerald Maintains Belite Bio(BLTE.US) With Buy Rating, Raises Target Price to $270
    Market Newswire · 2026/8/14
  • Rating change
    Analysts Offer Insights on Healthcare Companies: Crispr Therapeutics AG (CRSP), Tenax Therapeutics (TENX) and Belite Bio, Inc. ADR (BLTE)
    TipRanks · 2026/8/31
  • Rating change
    Analysts Offer Insights on Healthcare Companies: Belite Bio, Inc. ADR (BLTE), Vertex Pharmaceuticals (VRTX) and Corcept Therapeutics (CORT)
    TipRanks · 2026/10/15
  • Rating change
    Mizuho Securities Maintains Belite Bio(BLTE.US) With Buy Rating, Raises Target Price to $234
    Market Newswire · 2026/9/9
  • Rating change
    H.C. Wainwright Maintains Belite Bio(BLTE.US) With Buy Rating, Maintains Target Price $214
    Market Newswire · 2026/9/3
  • Rating change
    Maxim Group Maintains Belite Bio(BLTE.US) With Buy Rating, Maintains Target Price $200
    Market Newswire · 2026/8/16
  • Rating change
    Morgan Stanley Maintains Belite Bio(BLTE.US) With Buy Rating, Raises Target Price to $206
    Market Newswire · 2026/8/17
  • Earnings Flash (BLTE) Belite Bio, Inc Posts Q3 Adjusted Loss $0.60 per Share, Vs. FactSet Est of $-0.52
    MT Newswires · 2026/11/12
  • Belite Bio (BLTE.US) will release its financial report on November 12.
    Market Newswire · 2026/11/7
  • Rating change
    Analysts Offer Insights on Healthcare Companies: Structure Therapeutics, Inc. Sponsored ADR (GPCR), Belite Bio, Inc. ADR (BLTE) and BridgeBio Oncology Therapeutics (BBOT)
    TipRanks · 2026/9/9
  • Rating change
    CCORF Initiates Belite Bio(BLTE.US) With Buy Rating, Announces Target Price $303
    Market Newswire · 2026/9/4
  • Rating change
    Analysts Offer Insights on Healthcare Companies: Belite Bio, Inc. ADR (BLTE) and Daré Bioscience (DARE)
    TipRanks · 2026/8/16
  • Mizuho Securities Maintains Belite Bio(BLTE.US) With Buy Rating, Cuts Target Price to $221
    Market Newswire · 2026/10/29
  • Leerink Partners Maintains Belite Bio(BLTE.US) With Buy Rating, Raises Target Price to $215
    Market Newswire · 2026/11/13
  • H.C. Wainwright Maintains Belite Bio(BLTE.US) With Buy Rating, Maintains Target Price $245
    Market Newswire · 2026/11/13
  • Rating change
    Analysts Offer Insights on Healthcare Companies: Acrivon Therapeutics, Inc. (ACRV) and Belite Bio, Inc. ADR (BLTE)
    TipRanks · 2026/8/15
  • Rating change
    Mizuho Securities Maintains Belite Bio(BLTE.US) With Buy Rating, Maintains Target Price $220
    Market Newswire · 2026/9/6
  • Rating change
    A Quick Look at Today's Ratings for Belite Bio(BLTE.US), With a Forecast Between $201 to $270
    Market Newswire · 2026/8/15
  • Rating change
    BofA Securities Maintains Belite Bio(BLTE.US) With Buy Rating, Announces Target Price $200
    Market Newswire · 2026/9/3
  • Rating change
    H.C. Wainwright Maintains Belite Bio(BLTE.US) With Buy Rating, Raises Target Price to $245
    Market Newswire · 2026/9/8
  • Rating change
    Mizuho Securities Maintains Belite Bio(BLTE.US) With Buy Rating, Raises Target Price to $220
    Market Newswire · 2026/8/14
  • H.C. Wainwright Maintains Belite Bio(BLTE.US) With Buy Rating, Maintains Target Price $245
    Market Newswire · 2026/10/15
  • Rating change
    Mizuho Securities Remains a Buy on Belite Bio, Inc. ADR (BLTE)
    TipRanks · 2026/8/14
  • Morgan Stanley initiates coverage on eight biotech companies in one go! PTC Therapeutics (PTCT.US) and Belite Bio (BLTE.US) receive positive ratings, with several potential blockbuster drugs highlighted.
    Zhitong Finance · 2026/10/20
  • Rating change
    Cantor Fitzgerald Reaffirms Their Buy Rating on Belite Bio, Inc. ADR (BLTE)
    TipRanks · 2026/8/12

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Belite Bio discussion 0 comments

Add a comment